HOME >> MEDICINE >> NEWS
Second-generation antipsychotic medications appear to offer little advantage over older drugs

Among patients with schizophrenia whose medication is changed because of ineffectiveness or harmful side effects, second-generation antipsychotic drugs do not appear to offer significant benefits compared to first-generation antipsychotic drugs, according to a report in the October issue of Archives of General Psychiatry, one of the JAMA/Archives journals. The findings run contrary to the widely held perception that second-generation antipsychotic agents are safer and more effective in treating patients with schizophrenia than the less-expensive first-generation class of medications.

For almost 50 years, antipsychotic medications have been the primary method of treating schizophrenia, a psychiatric disorder that causes a disconnect from reality and severe disturbances in thought, mood and behavior. Patients taking first-generation antipsychotics--so called because they were developed first--often relapse or develop severe side effects, including sedation (feeling tranquilized) and involuntary muscle movements, according to background information in the article. The development of second-generation antipsychotics was thought to be a major advance primarily because the drugs reduced such side effects. Claims that second-generation drugs are more effective than first-generation drugs have shifted treatment patterns away from first-generation medications, although research comparing the drug classes has had mixed results.

Peter B. Jones, M.D., Ph.D., University of Cambridge and Cambridgeshire and Peterborough Mental Health NHS Trust, Cambridge, England, and colleagues studied 227 individuals age 18 to 65 with schizophrenia. "The key question was whether the additional acquisition costs of second-generation antipsychotics over first-generation antipsychotics would be offset by improvements in health-related quality of life or savings in the use of other health and social care services in people with schizophrenia for whom a change in drug trea
'"/>

Contact: Peter B. Jones, M.D., Ph.D.
pbj21@cam.ac.uk
JAMA and Archives Journals
2-Oct-2006


Page: 1 2 3 4

Related medicine news :

1. USC-led study suggests little benefit from antipsychotics in Alzheimers
2. Most effective antipsychotic drug has serious health consequences
3. Number of children and teens treated with antipsychotics increases sharply
4. Atypical antipsychotic drugs for dementia may be associated with small increased risk of death
5. NIMH study finds antipsychotic Risperidone safe, effective as intermediate term treatment for autism
6. Metabolic side effects of antipsychotics are known, but rarely monitored
7. Different antipsychotic medications may have different effects on brain volume
8. Study shows new antipsychotic drug prevents brain loss in schizophrenia
9. Commonly used pain medications do not prevent Alzheimers disease
10. Standard long-acting insulin as good as newer medications
11. MS patients not receiving medications to slow disease progression, research shows

Post Your Comments:
(Date:11/1/2014)... Tara Haelle HealthDay Reporter ... can both sense adult anger and alter their behavior in ... sponges," said study co-author Andrew Meltzoff, co-director of the University ... "They learn not only from their own direct social experiences ... He said he was most surprised at how emotionally ...
(Date:10/31/2014)... 31, 2014 Springboard Biodiesel, a ... small scale BioPro™ biodiesel processors, announced on Thursday ... improve the performance and efficiency of small-scale biodiesel ... trio will recover more than 99% of ... the glycerin by-product produced while making biodiesel. ...
(Date:10/31/2014)... Daily Gossip writes in its Xtreme Fat Loss review ... fat loss program ever developed. It promises to provide users ... is no wonder after all that this has become the ... nutrition and workout fat loss program was created by Joel ... to the author of this fat loss system, the method ...
(Date:10/31/2014)... (PRWEB) October 31, 2014 Activz ... Activz Silver line offering natural silver healing ... For over a century, silver has been used to ... Activz Silver products is the most advanced version available. ... a unique chemical structure that supports the existing healing ...
(Date:10/31/2014)... of duration of treatment and cost, patients with ... partial breast irradiation (APBI) with proton therapy versus ... from The University of Texas MD Anderson Proton ... analysis study based on typical patient characteristics, researchers ... for eight different types of partial and whole ...
Breaking Medicine News(10 mins):Health News:Study Shows How Toddlers Adjust to Adult Anger 2Health News:Study Shows How Toddlers Adjust to Adult Anger 3Health News:Springboard Biodiesel Announces Release of New and Unique Methanol Recovery and Glycerin Treatment Equipment 2Health News:Springboard Biodiesel Announces Release of New and Unique Methanol Recovery and Glycerin Treatment Equipment 3Health News:Xtreme Fat Loss Diet Review Reveals How to Transform Your Body in 25 Days 2Health News:New Collection of Nano-particle Natural Silver Products by Activz Whole-Food Nutrition 2Health News:New Collection of Nano-particle Natural Silver Products by Activz Whole-Food Nutrition 3Health News:New Collection of Nano-particle Natural Silver Products by Activz Whole-Food Nutrition 4Health News:Proton therapy shown to be less costly than some alternative radiotherapy techniques 2Health News:Proton therapy shown to be less costly than some alternative radiotherapy techniques 3
(Date:10/31/2014)... -- Digirad Corporation (Nasdaq: DRAD) today announced that it has sent ... ), a healthcare commercialization services company, responding to PDI,s ... Digirad calls upon PDI to immediately ... operate in the ordinary course of business and to ... on acquisitions or other extraordinary transactions. Digirad believes that ...
(Date:10/31/2014)... DIEGO, Oct. 31, 2014 Mast Therapeutics, Inc. ... financial results for the quarter ended September 30, 2014. ... Executive Officer, said:  "The third quarter was productive for ... study of MST-188 for sickle cell disease is on ... year. We now have opened 50 study sites in the ...
(Date:10/31/2014)... 2014 Today, Analysts Review released ... CELG ), Bristol-Myers Squibb Co. (NYSE: BMY ... Sanofi SA (NYSE: SNY ) and Actavis ... ahead of publication. To reserve complementary membership, limited openings ... Corporation Research Reports ,On October 23, 2014, Celgene Corporation ...
Breaking Medicine Technology:Digirad Delivers Letter To PDI, Inc. Responding To PDI's Summary Rejection Of Digirad's Offer To Acquire Company 2Digirad Delivers Letter To PDI, Inc. Responding To PDI's Summary Rejection Of Digirad's Offer To Acquire Company 3Digirad Delivers Letter To PDI, Inc. Responding To PDI's Summary Rejection Of Digirad's Offer To Acquire Company 4Digirad Delivers Letter To PDI, Inc. Responding To PDI's Summary Rejection Of Digirad's Offer To Acquire Company 5Mast Therapeutics Reports Third Quarter 2014 Financial Results 2Mast Therapeutics Reports Third Quarter 2014 Financial Results 3Mast Therapeutics Reports Third Quarter 2014 Financial Results 4Mast Therapeutics Reports Third Quarter 2014 Financial Results 5Mast Therapeutics Reports Third Quarter 2014 Financial Results 6Mast Therapeutics Reports Third Quarter 2014 Financial Results 7Mast Therapeutics Reports Third Quarter 2014 Financial Results 8Financial Results, Acquisition Agreement, and Legal Issue Update - Research Reports on Celgene, Bristol-Myers, UnitedHealth, Sanofi and Actavis 2Financial Results, Acquisition Agreement, and Legal Issue Update - Research Reports on Celgene, Bristol-Myers, UnitedHealth, Sanofi and Actavis 3Financial Results, Acquisition Agreement, and Legal Issue Update - Research Reports on Celgene, Bristol-Myers, UnitedHealth, Sanofi and Actavis 4Financial Results, Acquisition Agreement, and Legal Issue Update - Research Reports on Celgene, Bristol-Myers, UnitedHealth, Sanofi and Actavis 5Financial Results, Acquisition Agreement, and Legal Issue Update - Research Reports on Celgene, Bristol-Myers, UnitedHealth, Sanofi and Actavis 6
Cached News: